• Publications
  • Influence
Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
A novel homology model of the kinase domain of Janus kinase (JAK) 3 was used for the structure-based design of dimethoxyquinazoline compounds with potent and specific inhibitory activity againstExpand
  • 163
  • 12
  • PDF
Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]*
In a systematic effort to design potent inhibitors of the anti-apoptotic tyrosine kinase BTK (Bruton′s tyrosine kinase) as anti-leukemic agents with apoptosis-promoting and chemosensitizingExpand
  • 156
  • 3
Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting
In a systematic effort to design potent inhibitors of the anti-apoptotic tyrosine kinase BTK (Bruton*s tyrosine kinase) as anti-leukemic agents with apoptosis-promoting and chemosensitizingExpand
  • 26
  • 3
Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes.
In a systematic effort to identify and develop effective anticancer agents, four oxovanadium(IV) complexes with 1,10-phenanthroline (Phen) or 4,7-dimethyl-1,10-phenanthroline (Me2-Phen) as ligand(s)Expand
  • 91
  • 2
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
The novel thiourea compound N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thi ourea (HI-236) targeting the non-nucleoside inhibitor (NNI) binding pocket of HIV-1 reverse transcriptase (RT)Expand
  • 48
  • 2
Structure-Based Design of Novel Dihydroalkoxybenzyloxopyrimidine Derivatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficiency Virus Reverse Transcriptase
ABSTRACT Two highly potent dihydroalkoxybenzyloxopyrimidine (DABO) derivatives targeting the nonnucleoside inhibitor (NNI) binding site of human immunodeficiency virus (HIV) reverse transcriptaseExpand
  • 43
  • 1
  • PDF
Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase
Abstract A series of novel phenethylthiazolylthiourea (PETT) derivatives targeting the nonnucleoside inhibitor (NNI) binding site of HIV reverse transcriptase (RT) have been designed based on theExpand
  • 76
  • 1
Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase.
The generation of anti-HIV agents using structure-based drug design methods has yielded a number of promising non-nucleoside inhibitors (NNIs) of HIV reverse transcriptase (RT). Recent successes inExpand
  • 54
  • 1
Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.
On the basis of the lead compound 4-(N-acetylamino)-3-guanidinobenzoic acid (BANA 113), which inhibits influenza A sialidase with a Ki of 2.5 microM, several novel aromatic inhibitors of influenzaExpand
  • 53
  • 1
SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity.
  • F. Uckun, C. Mao, +5 authors R. Narla
  • Medicine, Chemistry
  • Current opinion in investigational drugs
  • 1 October 2000
Agents that either promote or inhibit tubulin polymerization exhibit anticancer activity by disrupting normal mitotic spindle assembly and cell division as well as inducing apoptosis. RecentlyExpand
  • 11
  • 1